Trial Profile

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in a Real-World Setting: United States

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibalizumab (Primary)
Indications HIV infections
Focus Adverse reactions; Therapeutic Use
Acronyms PROMISE-US
Sponsors Theratechnologies

Most Recent Events

12 Mar 2025 An interim unmatched subgroup analysis(n=112) presented in Theratechnologies Media Release.
12 Mar 2025 Results published in the Theratechnologies media release
07 Feb 2025 Planned number of patients changed from 600 to 200.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com